ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $615,024.60 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Laura Shawver sold 50,002 shares of the firm's stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $12.30, for a total value of $615,024.60. Following the completion of the transaction, the director now owns 210,346 shares in the company, valued at approximately $2,587,255.80. This trade represents a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Laura Shawver also recently made the following trade(s):

• On Thursday, March 6th, Laura Shawver sold 49,600 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $11.21, for a total transaction of $556,016.00.
• On Monday, February 3rd, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $12.31, for a total value of $615,500.00.

ARS Pharmaceuticals Stock Up 6.1 %

SPRY stock traded up $0.81 during midday trading on Friday, reaching $14.05. The company's stock had a trading volume of 2,203,480 shares, compared to its average volume of 1,140,734. ARS Pharmaceuticals, Inc. has a 52 week low of $7.55 and a 52 week high of $18.51. The stock has a market cap of $1.38 billion, a PE ratio of -27.55 and a beta of 0.86. The business's 50-day simple moving average is $12.00 and its 200-day simple moving average is $13.04.

Remove Ads

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.56. The business had revenue of $86.58 million for the quarter, compared to analyst estimates of $15.46 million. As a group, equities analysts forecast that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Institutional Trading of ARS Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC grew its position in ARS Pharmaceuticals by 189.7% in the third quarter. Barclays PLC now owns 111,666 shares of the company's stock valued at $1,618,000 after purchasing an additional 73,127 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of ARS Pharmaceuticals by 93.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company's stock worth $3,631,000 after buying an additional 165,950 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of ARS Pharmaceuticals by 766.1% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company's stock valued at $3,401,000 after acquiring an additional 207,456 shares in the last quarter. Peregrine Capital Management LLC acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter valued at about $4,469,000. Finally, State Street Corp raised its holdings in ARS Pharmaceuticals by 10.4% during the third quarter. State Street Corp now owns 2,049,542 shares of the company's stock worth $29,718,000 after acquiring an additional 193,321 shares in the last quarter. Institutional investors and hedge funds own 68.16% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Raymond James lifted their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a report on Tuesday, January 14th. William Blair restated an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners lifted their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Oppenheimer assumed coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They set an "outperform" rating and a $40.00 price objective on the stock. Finally, Scotiabank started coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.